.jpg)
British biotech CellCentric expands to Boston with plans to grow into late-stage clinical development
British biotech CellCentric is settling into a new office in Boston, part of the company’s expansion into the U.S. as multiple myeloma asset inobrodib progresses to late-stage clinical development.
British biotech CellCentric is settling into a new office in Boston, part of the company’s expansion into the U.S. as multiple myeloma asset inobrodib progresses to late-stage clinical development.
